WHO advises against Gilead's remdesivir for all hospitalised COVID-19 patients

Reuters |
Published: 11.20.20 , 07:49
Gilead's drug remdesivir is not recommended for patients hospitalized with COVID-19, regardless of how ill they are, as there is no evidence it improves survival or reduces the need for ventilation, a World Health Organization panel said on Friday.
"The ... panel found a lack of evidence that remdesivir improved outcomes that matter to patients such as reduced mortality, need for mechanical ventilation, time to clinical improvement, and others," the guideline said.
The advice is another setback for the drug, which grabbed worldwide attention as a potentially effective treatment for COVID-19 in the summer after early trials showed some promise.